Pharmacokinetics and lipid-lowering effect of fluvastatin in hypercholesterolaemic patients on maintenance haemodialysis

Journal of International Medical Research

Volumn 32, Issue 1, 2004, Pages 45-52

  Ichimaru, N ^a   Takahara, S ^a   Moriyama, T ^a   Kondo, M ^b   Nonomura, N ^a   Tanaka, T ^a   Wang, J D ^a   Imai, E ^a   Okuyama, A ^a   Kondo, Y ^b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kondo Pediatric Clinic   (Japan)

Author keywords

Clinical; Dialysis; Fluvastatin; HMG CoA reductase inhibitors; Hyperlipidaemia; Pharmacokinetics

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; DIALYSIS MEMBRANE; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MALE; PATIENT MONITORING; SIDE EFFECT;

EID: 10744233348     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000403200107     Document Type: Article

References (18)

1. Linder A, Charra B, Sherrard DJ, Scribner BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697 - 701.
2. Bonomini, Feletti C, Scolari MP, Stefoni S, Vangelsta A: Atherosclerosis in uremia: a longitudinal study. Am J Clin Nutr 1980; 33: 1493 - 1500.
3. Bagdade JD, Porte D, Jr, Bierman EL: Hypertriglyceridemia. A metabolic consequence of chronic renal failure. N Engl J Med 1968; 279: 181 - 185.
4. Ma KW, Green EL, Raij L: Cardiovascular risk factors in the chronic renal failure and hemodialysis population. Am J Kidney Dis 1992; 19: 505 - 513.
5. Kaysen GA: Hyperlipidemia of chronic renal failure. Blood Purif 1994; 12: 60 - 67.
6. Haas LB, Wahl PW, Sherrard DJ: A longitudinal study of lipid abnormalities in renal failure. Nephron 1983; 33: 145 - 159.
7. Senti M, Romero R, Pedro-Botet J, Pelegri A, Nogues X, Rubies-Prat J: Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int 1992; 41: 1394 - 1399.
8. Wanner C, Horl WH, Luley CH, Wieland H: Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis. Kidney Int 1991; 39: 754 - 760.
9. Nishizawa Y, Shoji T, Emoto M, Kawasaki K, Konishi T, Tabata T, et al: Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients. Clin Nephrol 1995; 43: 268 - 277.
10. Nishikawa O, Mune M, Miyano T, Nishide T, Nishide I, Maeda A, et al: Effect of simvastatin on lipid profile of hemodialysis patients. Kidney Int 1999; 56 (Suppl 71): S219 - S221.
11. Kathawala FG: HMG-CoA reductase inhibitors: an exciting development in the treatment of hyperlipoproteinemia. Med Res Rev 1991; 11: 121 - 146.
12. Kalafsky G, Smith HT, Choc MG: High-performance liquid chromatographic method for the determination of fluvastatin in human plasma. J Chromatogr 1993; 614: 307 - 313.
13. Lintott CJ, Scott RS, Bremer JM, Shand BI: Fluvastatin for dyslipoteinemia, with or without concomitant chronic renal insufficiency. Am J Cardiol 1995; 76: 97A - 101A.
14. Deslypere JP, Vermeulen A: Rhabdomyolysis and simvastatin. Ann Intern Med 1991; 114: 342.
15. Sugimoto M, Shibata H: Pharmacokinetics of fluvastatin sodium (XU62-820) in the elderly. J Clin Ther Med 1995; 11 (Suppl 1): 83 - 101.
16. Quertin S, Lambert R, Cusson JR, Gregoire S, Vickers S, Stubbs RJ, et al: Single-dose pharmacokinetics of 14C-lovastatin in chronic renal failure. Clin Pharmacol Ther 1991; 50: 437 - 441.
17. Gehr TWB, Sica DA, Slugg PH, Hammett JL, Raymond R, Ford NF: The pharmacokinetics of pravastatin in patients on chronic hemodialysis. Eur J Clin Pharmacol 1997; 53: 117 - 121.
18. Tse FL, Jaffe JM, Troendle A: Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 1992; 32: 630 - 638.